OncoViews

Uniting oncologists for borderless exchange

Uniting healthcare professionals for

borderless exchange in oncology

ï•™

CME-certified

All roundtable sessions accredited

UPCOMING

Join us for
our roundtable in
||
latest advances in
||
your questions on
||
new therapies for
||
practice changes in
||
your patient cases in

DLBCL: Bispecifics VS. CAR-T

Maria Cristina Pirosa

ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND

Thorsten Zenz

UNIVERSITY HOSPITAL ZURICH, SWITZERLAND

Federico Simonetta

UNIVERSITY HOSPITAL GENEVA, SWITZERLAND

Agenda

Welcome & introduction by host

Maria Cristina Pirosa

The case for CAR: why CAR T-cells can excel DLBCL care

Federico Simonetta

The case for Bispecifics: bispecific therapy can provide a dynamic approach to DLBCL management

Thorsten Zenz

Which holds a greater promise for transforming DLBCL treatment: CAR T-Cells or Bispecifics?

Debate with all panelists

ï•™

2 CME Points

SGH • SSH

Join us for an engaging debate on the forefront of DLBCL treatment: CAR T-cells vs. Bispecifics. Led by Dr. Maria Pirosa, this roundtable discussion promises to examine the strengths and potential of each therapy, guiding the future of lymphoma care. Don't miss this opportunity to gain insights from leading experts in the field. Engage in the conversation, submit your questions, and explore the latest insights shaping the current approach to diffuse large B-cell lymphoma treatment.

ADD THIS TO YOUR CALENDAR

Register here

Do You Have An Account Already?
No need to sign up again: as a verified OncoViewer, you will have access to all our upcoming sessions. Simply login to participate in this session.


First Time On OncoViews?

Get Registered Now

This session is kindly supported by our partners with no influence on the content

AstraZeneca
AbbVie
BMS
Gilead

COMING SOON

Maria Cristina Pirosa

ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND

Thorsten Zenz

UNIVERSITY HOSPITAL ZURICH, SWITZERLAND

Federico Simonetta

UNIVERSITY HOSPITAL GENEVA, SWITZERLAND